Literature DB >> 17189599

Treatment with gabapentin of 11 dogs with refractory idiopathic epilepsy.

S R Platt1, V Adams, L S Garosi, C J Abramson, J Penderis, A De Stefani, L Matiasek.   

Abstract

Eleven dogs diagnosed with refractory idiopathic epilepsy were treated orally with gabapentin for a minimum of three months at an initial dose of 10 mg/kg every eight hours. They were all experiencing episodes of generalised tonic-clonic seizures and had been treated chronically with a combination of phenobarbital and potassium bromide at doses sufficient to reach acceptable therapeutic serum levels without causing significant side effects. In each dog, the number of seizures per week, the average duration of the seizures and the number of days on which seizures occurred were compared for the three months before and after they were treated with gabapentin. A minimum 50 per cent reduction in the number of seizures per week was interpreted as a positive response to gabapentin, and six of the dogs showed a positive response. After the addition of gabapentin, both the number of seizures per week (P= 0.005) and the number of days with any seizures in a one-week period (P=0.03) were significantly reduced. Mild side effects of ataxia and sedation were observed in five of the dogs, but they were not severe enough to warrant the treatment being discontinued during the trial.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17189599

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  15 in total

1.  A novel implanted device to wirelessly record and analyze continuous intracranial canine EEG.

Authors:  Kathryn A Davis; Beverly K Sturges; Charles H Vite; Vanessa Ruedebusch; Gregory Worrell; Andrew B Gardner; Kent Leyde; W Douglas Sheffield; Brian Litt
Journal:  Epilepsy Res       Date:  2011-06-14       Impact factor: 3.045

2.  Lafora disease as a cause of visually exacerbated myoclonic attacks in a dog.

Authors:  Aubrey A Webb; Chantal McMillan; Cheryl L Cullen; Sarah E Boston; Julie Turnbull; Berge A Minassian
Journal:  Can Vet J       Date:  2009-09       Impact factor: 1.008

3.  Pharmacokinetics of oral gabapentin in greyhound dogs.

Authors:  Butch Kukanich; Rachael L Cohen
Journal:  Vet J       Date:  2009-10-23       Impact factor: 2.688

4.  Clinical Risk Factors for Early Seizure Recurrence in Dogs Hospitalized for Seizure Evaluation.

Authors:  M Kwiatkowska; A Tipold; E Huenerfauth; A Pomianowski
Journal:  J Vet Intern Med       Date:  2018-02-18       Impact factor: 3.333

5.  Gabapentin: An update of its pharmacological properties and therapeutic use in epilepsy.

Authors:  Azim Honarmand; Mohammadreza Safavi; Mohammad Zare
Journal:  J Res Med Sci       Date:  2011-08       Impact factor: 1.852

6.  International Veterinary Epilepsy Task Force consensus proposal: medical treatment of canine epilepsy in Europe.

Authors:  Sofie F M Bhatti; Luisa De Risio; Karen Muñana; Jacques Penderis; Veronika M Stein; Andrea Tipold; Mette Berendt; Robyn G Farquhar; Andrea Fischer; Sam Long; Wolfgang Löscher; Paul J J Mandigers; Kaspar Matiasek; Akos Pakozdy; Edward E Patterson; Simon Platt; Michael Podell; Heidrun Potschka; Clare Rusbridge; Holger A Volk
Journal:  BMC Vet Res       Date:  2015-08-28       Impact factor: 2.741

7.  Forecasting seizures in dogs with naturally occurring epilepsy.

Authors:  J Jeffry Howbert; Edward E Patterson; S Matt Stead; Ben Brinkmann; Vincent Vasoli; Daniel Crepeau; Charles H Vite; Beverly Sturges; Vanessa Ruedebusch; Jaideep Mavoori; Kent Leyde; W Douglas Sheffield; Brian Litt; Gregory A Worrell
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

Review 8.  Treatment in canine epilepsy--a systematic review.

Authors:  Marios Charalambous; David Brodbelt; Holger A Volk
Journal:  BMC Vet Res       Date:  2014-10-22       Impact factor: 2.741

9.  Clinical risk factors associated with anti-epileptic drug responsiveness in canine epilepsy.

Authors:  Rowena M A Packer; Nadia K Shihab; Bruno B J Torres; Holger A Volk
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

10.  Assessment into the usage of levetiracetam in a canine epilepsy clinic.

Authors:  Rowena M A Packer; George Nye; Sian Elizabeth Porter; Holger A Volk
Journal:  BMC Vet Res       Date:  2015-02-07       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.